Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting.
Motoyasu KatoShinichi SasakiMisa TateyamaYuta AraiHiroaki MotomuraIssei SumiyoshiYusuke OchiJunko WatanabeHiroaki IharaShinsaku TogoKazuhisa TakahashiPublished in: Drug design, development and therapy (2021)
Poor PS can result in discontinuation of nintedanib after 12 months. Long-term nintedanib treatment may be effective for survival.